Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed/refractory acute lymphoblastic leukemia

Shannon L Maude, David M Barrett, Susan R Rheingold, Richard Aplenc, David T Teachey, Colleen Callahan, Diane Baniewicz, Claire White, Mala K Talekar, Pamela A Shaw, Jennifer L Brogdon, Regina M Young, John Scholler, Katherine T Marcucci, Bruce L Levine, Noelle Frey, David L Porter, Simon F Lacey, J Joseph Melenhorst, Carl H June, Stephan A Grupp
2016-12-02
Abstract:BackgroundTargeted immunotherapy with CTL019, CD19-specific chimeric antigen receptor (CAR)-modified T cells, can produce potent and sustained responses in children with relapsed/refractory acute lymphoblastic leukemia (ALL). However, a subset of patients has limited persistence, which can increase the risk of relapse. Most CAR single chain variable fragment (scFv) domains, including that of CTL019, are of murine origin; therefore, anti-mouse reactivity is one potential cause of immune-mediated rejection that may be overcome by fully human or humanized CAR designs. We developed a humanized anti-CD19 scFv domain and now report on treatment with humanized CD19-directed CAR T cells (CTL119).DesignA pilot/phase 1 study of CAR-modified T cells containing a humanized anti-CD19 scFv domain (CTL119) enrolled children and young adults with relapsed/refractory B-ALL with or without prior …
What problem does this paper attempt to address?